Coverage
-
September 15, 2014
The Federal Circuit on Friday refused to reconsider its decision to lift an injunction on generic versions of Allergan Inc.'s eyelash growth stimulant Latisse after previously ruling that two patents covering the drug were obvious in light of prior art.
2 other articles on this case.
View all »